Literature DB >> 1599518

Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis.

D Oguey1, F Kölliker, N J Gerber, J Reichen.   

Abstract

OBJECTIVE: To evaluate the influence of food on the bioavailability of an oral dose of methotrexate in patients with rheumatoid arthritis.
METHODS: Methotrexate (15 mg) was given intravenously and orally, with or without a meal, to 10 patients. Blood samples were drawn at specific intervals to evaluate drug levels.
RESULTS: Food reduced the peak concentration, from a mean of 0.71 mumoles/liter to 0.49 mumoles/liter (P less than 0.02), and slightly increased the time to peak concentration, from a mean of 1.3 hours to 2.0 hours. Bioavailability was highly variable (range 28-94%) but was not affected by food intake.
CONCLUSION: Bioavailability of oral methotrexate shows marked interindividual variation but is not affected by the presence of food.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1599518     DOI: 10.1002/art.1780350603

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  27 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Variability of oral bioavailability for low dose methotrexate in rats.

Authors:  T Kuroda; K Namba; T Torimaru; S Yamamoto; M Akahori
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

Review 3.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

4.  Methotrexate: optimizing the efficacy in rheumatoid arthritis.

Authors:  Jürgen Braun
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-06       Impact factor: 5.346

Review 5.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis.

Authors:  Jaroslav Chládek; Jiøí Grim; Jiøina Martínková; Marie Simková; Jaroslava Vanìèková; Vìra Koudelková; Marie Noièková
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

7.  The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.

Authors:  C Godfrey; K Sweeney; K Miller; R Hamilton; J Kremer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

8.  Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.

Authors:  Jeffrey A Sparks; Medha Barbhaiya; Elizabeth W Karlson; Susan Y Ritter; Soumya Raychaudhuri; Cassandra C Corrigan; Fengxin Lu; Jacob Selhub; Daniel I Chasman; Nina P Paynter; Paul M Ridker; Daniel H Solomon
Journal:  Semin Arthritis Rheum       Date:  2017-02-10       Impact factor: 5.532

Review 9.  Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?

Authors:  Alexandros Drosos
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis.

Authors:  C Lebbe; C Beyeler; N J Gerber; J Reichen
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.